Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer Academic Article Article uri icon


MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Barium Sulfate
  • Esophageal Neoplasms
  • Induction Chemotherapy
  • Multimodal Imaging
  • Positron-Emission Tomography
  • Tomography, X-Ray Computed


  • The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential. The objective of this randomized study was to determine whether WR-2721 would decrease the hematologic toxicity of mitomycin in patients with colorectal cancer resistant to fluorouracil-based therapy. Ninety-seven patients with refractory colorectal cancer were randomized to receive either mitomycin 20 mg/m2 only or the same dose of mitomycin after pretreatment with WR-2721, 910 mg/m2. The principal toxicity in both groups was thrombocytopenia. The platelet nadirs were lower in patients receiving single-agent mitomycin (P = 0.026). Surprisingly, no clinical complete or partial responses were noted in either group, and survival was not different between the two groups. Thus, while WR-2721 decreased the thrombocytopenia associated with mitomycin therapy, mitomycin was ineffective in the treatment of refractory colorectal carcinoma.

publication date

  • September 1994



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1007/BF00686271

PubMed ID

  • 8306416

Additional Document Info

start page

  • 415

end page

  • 9


  • 33


  • 5